Raymond James Maintains Outperform Rating for Leap Therapeutics: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Raymond James has maintained its Outperform rating for Leap Therapeutics (NASDAQ:LPTX) but reduced its price target from $18.50 to $17.50. Despite the lower target, the new price still implies a significant upside of 1066.67% from the current trading price of $1.50. Leap Therapeutics is a biopharmaceutical company focused on developing cancer treatments, with its main clinical program being DKN-01, targeting tumor-promoting pathways and the immune system.
November 14, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Raymond James maintains Outperform rating on Leap Therapeutics with a reduced price target of $17.50, indicating a substantial potential upside from the current price.
The maintenance of an Outperform rating by Raymond James suggests a positive outlook on Leap Therapeutics, which could instill investor confidence and drive short-term interest in the stock. The reduction in the price target is outweighed by the still substantial potential upside, indicating that the stock may still be undervalued. This news is highly relevant and important to investors as it directly affects their investment decisions in LPTX. The confidence score reflects the credibility of Raymond James as a financial institution and the historical influence of analyst ratings on stock performance.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100